ID   PTPRU_HUMAN             Reviewed;        1446 AA.
AC   Q92729; A6H8L1; O00197; P78399; Q59HA4; Q5SYU4; Q5SYU5; Q92735; Q92850;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 2.
DT   28-JUN-2023, entry version 207.
DE   RecName: Full=Receptor-type tyrosine-protein phosphatase U;
DE            Short=R-PTP-U;
DE            EC=3.1.3.48;
DE   AltName: Full=Pancreatic carcinoma phosphatase 2;
DE            Short=PCP-2;
DE   AltName: Full=Protein-tyrosine phosphatase J;
DE            Short=PTP-J;
DE            Short=hPTP-J;
DE   AltName: Full=Protein-tyrosine phosphatase pi;
DE            Short=PTP pi;
DE   AltName: Full=Protein-tyrosine phosphatase receptor omicron;
DE            Short=PTP-RO;
DE   AltName: Full=Receptor-type protein-tyrosine phosphatase psi;
DE            Short=R-PTP-psi;
DE   Flags: Precursor;
GN   Name=PTPRU; Synonyms=FMI, PCP2, PTPRO;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Mammary gland;
RX   PubMed=8870675; DOI=10.1042/bj3190249;
RA   Crossland S., Smith P.D., Crompton M.R.;
RT   "Molecular cloning and characterization of PTP pi, a novel receptor-like
RT   protein-tyrosine phosphatase.";
RL   Biochem. J. 319:249-254(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), CATALYTIC ACTIVITY, GLYCOSYLATION,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Pancreas;
RX   PubMed=8700514;
RA   Wang H.-Y., Lian Z., Lerch M.M., Chen Z., Xie W., Ullrich A.;
RT   "Characterization of PCP-2, a novel receptor protein tyrosine phosphatase
RT   of the MAM domain family.";
RL   Oncogene 12:2555-2562(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND INDUCTION.
RC   TISSUE=Skeletal muscle;
RX   PubMed=9070223; DOI=10.1006/bbrc.1997.6004;
RA   Wang B., Kishihara K., Zhang D., Hara H., Nomoto K.;
RT   "Molecular cloning and characterization of a novel human receptor protein
RT   tyrosine phosphatase gene, hPTP-J: down-regulation of gene expression by
RT   PMA and calcium ionophore in Jurkat T lymphoma cells.";
RL   Biochem. Biophys. Res. Commun. 231:77-81(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RC   TISSUE=Brain;
RX   PubMed=9434160; DOI=10.1016/s0378-1119(97)00420-4;
RA   Avraham S., London R., Tulloch G.A., Ellis M., Fu Y., Jiang S., White R.A.,
RA   Painter C., Steinberger A.A., Avraham H.;
RT   "Characterization and chromosomal localization of PTPRO, a novel receptor
RT   protein tyrosine phosphatase, expressed in hematopoietic stem cells.";
RL   Gene 204:5-16(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2).
RA   Banville D., Masson S., L'Abbe D., Stocco R., Shen S.-H.;
RT   "Cloning and expression of R-PTP-psi, a novel receptor protein tyrosine
RT   phosphatase related to the homophilic binding R-PTP-kappa and -mu.";
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 194-1446 (ISOFORM 2).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   INDUCTION.
RX   PubMed=10395944; DOI=10.1016/s0167-4889(99)00064-6;
RA   Wang B., Kishihara K., Zhang D., Sakamoto T., Nomoto K.;
RT   "Transcriptional regulation of a receptor protein tyrosine phosphatase gene
RT   hPTP-J by PKC-mediated signaling pathways in Jurkat and Molt-4 T lymphoma
RT   cells.";
RL   Biochim. Biophys. Acta 1450:331-340(1999).
RN   [11]
RP   FUNCTION, INTERACTION WITH KIT, PHOSPHORYLATION, PROTEOLYTIC PROCESSING,
RP   AND INDUCTION BY PHORBOL ESTER.
RX   PubMed=10397721;
RA   Taniguchi Y., London R., Schinkmann K., Jiang S., Avraham H.;
RT   "The receptor protein tyrosine phosphatase, PTP-RO, is upregulated during
RT   megakaryocyte differentiation and is associated with the c-Kit receptor.";
RL   Blood 94:539-549(1999).
RN   [12]
RP   FUNCTION, INTERACTION WITH CTNNB1, INDUCTION, AND MUTAGENESIS OF CYS-1085
RP   AND CYS-1380.
RX   PubMed=12501215; DOI=10.1021/bi026095u;
RA   Yan H.-X., He Y.-Q., Dong H., Zhang P., Zeng J.-Z., Cao H.-F., Wu M.-C.,
RA   Wang H.-Y.;
RT   "Physical and functional interaction between receptor-like protein tyrosine
RT   phosphatase PCP-2 and beta-catenin.";
RL   Biochemistry 41:15854-15860(2002).
RN   [13]
RP   FUNCTION, INTERACTION WITH CTNNB1, AND MUTAGENESIS OF CYS-1085 AND
RP   CYS-1380.
RX   PubMed=16574648; DOI=10.1074/jbc.m602607200;
RA   Yan H.-X., Yang W., Zhang R., Chen L., Tang L., Zhai B., Liu S.-Q.,
RA   Cao H.-F., Man X.-B., Wu H.-P., Wu M.-C., Wang H.-Y.;
RT   "Protein-tyrosine phosphatase PCP-2 inhibits beta-catenin signaling and
RT   increases E-cadherin-dependent cell adhesion.";
RL   J. Biol. Chem. 281:15423-15433(2006).
RN   [14]
RP   INTERACTION WITH AP3B1.
RX   PubMed=17622474; DOI=10.1111/j.1745-7270.2007.00303.x;
RA   Dong H., Yuan H., Jin W., Shen Y., Xu X., Wang H.-Y.;
RT   "Involvement of beta3A subunit of adaptor protein-3 in intracellular
RT   trafficking of receptor-like protein tyrosine phosphatase PCP-2.";
RL   Acta Biochim. Biophys. Sin. 39:540-546(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-848 AND SER-853, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-853, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-830; TRP-835 AND CYS-856.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Tyrosine-protein phosphatase which dephosphorylates CTNNB1.
CC       Regulates CTNNB1 function both in cell adhesion and signaling. May
CC       function in cell proliferation and migration and play a role in the
CC       maintenance of epithelial integrity. May play a role in
CC       megakaryocytopoiesis. {ECO:0000269|PubMed:10397721,
CC       ECO:0000269|PubMed:12501215, ECO:0000269|PubMed:16574648}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-tyrosyl-[protein] = L-tyrosyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620; EC=3.1.3.48; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU10044, ECO:0000269|PubMed:8700514};
CC   -!- SUBUNIT: Forms homooligomeric complexes which mediate cell homotypic
CC       adhesion (Probable). Interacts (via the cytoplasmic juxtamembrane
CC       domain) with CTNNB1; may mediate interaction with the cadherin/catenin
CC       adhesion complex. Interacts with KIT. May interact with AP3B1.
CC       {ECO:0000269|PubMed:10397721, ECO:0000269|PubMed:12501215,
CC       ECO:0000269|PubMed:16574648, ECO:0000269|PubMed:17622474, ECO:0000305}.
CC   -!- INTERACTION:
CC       Q92729; P10721: KIT; NbExp=2; IntAct=EBI-7052301, EBI-1379503;
CC   -!- SUBCELLULAR LOCATION: Cell junction {ECO:0000269|PubMed:8700514}. Cell
CC       membrane {ECO:0000269|PubMed:8700514}; Single-pass type I membrane
CC       protein {ECO:0000269|PubMed:8700514}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q92729-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q92729-2; Sequence=VSP_037082;
CC       Name=3;
CC         IsoId=Q92729-3; Sequence=VSP_037082, VSP_037084;
CC       Name=4; Synonyms=PTPRO;
CC         IsoId=Q92729-4; Sequence=VSP_037082, VSP_037083, VSP_037085;
CC   -!- TISSUE SPECIFICITY: High levels in brain, pancreas, and skeletal
CC       muscle; less in colon, kidney, liver, stomach, and uterus; not
CC       expressed in placenta and spleen. Also detected in heart, prostate,
CC       lung, thymus, testis and ovary. Ubiquitously expressed in brain.
CC       Expressed by hematopoietic stem cells. {ECO:0000269|PubMed:8700514,
CC       ECO:0000269|PubMed:8870675, ECO:0000269|PubMed:9070223,
CC       ECO:0000269|PubMed:9434160}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal brain, lung and kidney.
CC       {ECO:0000269|PubMed:9434160}.
CC   -!- INDUCTION: Up-regulated upon cell contact (at protein level). Down-
CC       regulated by phorbol ester (at protein level) and calcium ionophore but
CC       up-regulated by phorbol ester in megakaryocytic cells
CC       (PubMed:10397721). {ECO:0000269|PubMed:10395944,
CC       ECO:0000269|PubMed:10397721, ECO:0000269|PubMed:12501215,
CC       ECO:0000269|PubMed:9070223}.
CC   -!- PTM: The extracellular domain is proteolytically processed through
CC       cleavage within the fibronectin type-III 4 domain (By similarity). In
CC       addition to the 190 kDa full-length protein, proteolytic products of
CC       100 kDa, 80 kDa and 73 kDa are observed. {ECO:0000250,
CC       ECO:0000269|PubMed:10397721}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:8700514}.
CC   -!- PTM: Phosphorylated on tyrosine residues upon activation of KIT with
CC       stem cell factor (SCF). The 73 kDa proteolytic product is not
CC       phosphorylated. {ECO:0000269|PubMed:10397721}.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Receptor class 2B subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA65016.1; Type=Miscellaneous discrepancy; Note=Several sequencing problems.; Evidence={ECO:0000305};
CC       Sequence=CAA65832.1; Type=Miscellaneous discrepancy; Note=Several sequencing problems.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X95712; CAA65016.1; ALT_SEQ; mRNA.
DR   EMBL; X97198; CAA65832.1; ALT_SEQ; mRNA.
DR   EMBL; U73727; AAB51343.1; -; mRNA.
DR   EMBL; U71075; AAC51938.1; -; mRNA.
DR   EMBL; U60289; AAB07074.1; -; Genomic_DNA.
DR   EMBL; AL645859; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590729; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL049570; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX07651.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07652.1; -; Genomic_DNA.
DR   EMBL; BC146655; AAI46656.1; -; mRNA.
DR   EMBL; AB208855; BAD92092.1; -; mRNA.
DR   CCDS; CCDS334.1; -. [Q92729-1]
DR   CCDS; CCDS335.1; -. [Q92729-2]
DR   CCDS; CCDS44098.2; -. [Q92729-4]
DR   CCDS; CCDS53290.1; -. [Q92729-3]
DR   PIR; JC5290; JC5290.
DR   PIR; S72441; S72441.
DR   RefSeq; NP_001181930.1; NM_001195001.1. [Q92729-3]
DR   RefSeq; NP_005695.3; NM_005704.4. [Q92729-1]
DR   RefSeq; NP_573438.3; NM_133177.3. [Q92729-4]
DR   RefSeq; NP_573439.2; NM_133178.3. [Q92729-2]
DR   PDB; 6SUB; X-ray; 1.72 A; A=871-1153.
DR   PDB; 6SUC; X-ray; 1.97 A; A=871-1153.
DR   PDBsum; 6SUB; -.
DR   PDBsum; 6SUC; -.
DR   AlphaFoldDB; Q92729; -.
DR   SMR; Q92729; -.
DR   BioGRID; 115386; 155.
DR   IntAct; Q92729; 22.
DR   MINT; Q92729; -.
DR   STRING; 9606.ENSP00000334941; -.
DR   ChEMBL; CHEMBL1961785; -.
DR   DEPOD; PTPRU; -.
DR   GlyCosmos; Q92729; 3 sites, No reported glycans.
DR   GlyGen; Q92729; 5 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; Q92729; -.
DR   PhosphoSitePlus; Q92729; -.
DR   BioMuta; PTPRU; -.
DR   DMDM; 229462800; -.
DR   EPD; Q92729; -.
DR   jPOST; Q92729; -.
DR   MassIVE; Q92729; -.
DR   MaxQB; Q92729; -.
DR   PaxDb; Q92729; -.
DR   PeptideAtlas; Q92729; -.
DR   ProteomicsDB; 75416; -. [Q92729-1]
DR   ProteomicsDB; 75417; -. [Q92729-2]
DR   ProteomicsDB; 75418; -. [Q92729-3]
DR   ProteomicsDB; 75419; -. [Q92729-4]
DR   Antibodypedia; 31032; 45 antibodies from 17 providers.
DR   DNASU; 10076; -.
DR   Ensembl; ENST00000345512.7; ENSP00000334941.5; ENSG00000060656.20. [Q92729-1]
DR   Ensembl; ENST00000373779.8; ENSP00000362884.3; ENSG00000060656.20. [Q92729-2]
DR   Ensembl; ENST00000428026.6; ENSP00000392332.2; ENSG00000060656.20. [Q92729-3]
DR   Ensembl; ENST00000460170.2; ENSP00000432906.1; ENSG00000060656.20. [Q92729-4]
DR   GeneID; 10076; -.
DR   KEGG; hsa:10076; -.
DR   MANE-Select; ENST00000373779.8; ENSP00000362884.3; NM_133178.4; NP_573439.2. [Q92729-2]
DR   UCSC; uc001bru.4; human. [Q92729-1]
DR   AGR; HGNC:9683; -.
DR   CTD; 10076; -.
DR   DisGeNET; 10076; -.
DR   GeneCards; PTPRU; -.
DR   HGNC; HGNC:9683; PTPRU.
DR   HPA; ENSG00000060656; Low tissue specificity.
DR   MIM; 602454; gene.
DR   neXtProt; NX_Q92729; -.
DR   OpenTargets; ENSG00000060656; -.
DR   PharmGKB; PA34028; -.
DR   VEuPathDB; HostDB:ENSG00000060656; -.
DR   eggNOG; KOG4228; Eukaryota.
DR   GeneTree; ENSGT00940000157151; -.
DR   HOGENOM; CLU_001645_0_2_1; -.
DR   InParanoid; Q92729; -.
DR   OMA; WEQVRSH; -.
DR   OrthoDB; 2875525at2759; -.
DR   PhylomeDB; Q92729; -.
DR   TreeFam; TF312900; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   PathwayCommons; Q92729; -.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   SignaLink; Q92729; -.
DR   BioGRID-ORCS; 10076; 14 hits in 1158 CRISPR screens.
DR   ChiTaRS; PTPRU; human.
DR   GeneWiki; PTPRU; -.
DR   GenomeRNAi; 10076; -.
DR   Pharos; Q92729; Tbio.
DR   PRO; PR:Q92729; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q92729; protein.
DR   Bgee; ENSG00000060656; Expressed in endocervix and 165 other tissues.
DR   Genevisible; Q92729; HS.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0005001; F:transmembrane receptor protein tyrosine phosphatase activity; NAS:UniProtKB.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; NAS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0034109; P:homotypic cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:2000049; P:positive regulation of cell-cell adhesion mediated by cadherin; IDA:UniProtKB.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0034394; P:protein localization to cell surface; IDA:UniProtKB.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0007185; P:transmembrane receptor protein tyrosine phosphatase signaling pathway; NAS:UniProtKB.
DR   CDD; cd00063; FN3; 3.
DR   CDD; cd06263; MAM; 1.
DR   CDD; cd14632; R-PTPc-U-1; 1.
DR   CDD; cd14637; R-PTPc-U-2; 1.
DR   Gene3D; 2.60.120.200; -; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 4.
DR   Gene3D; 3.90.190.10; Protein tyrosine phosphatase superfamily; 2.
DR   InterPro; IPR013320; ConA-like_dom_sf.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR000998; MAM_dom.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR000242; PTP_cat.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; Tyr_Pase_dom.
DR   PANTHER; PTHR24051:SF10; PROTEIN-TYROSINE-PHOSPHATASE-RELATED; 1.
DR   PANTHER; PTHR24051; SUSHI DOMAIN-CONTAINING PROTEIN 1; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF00629; MAM; 1.
DR   Pfam; PF00102; Y_phosphatase; 2.
DR   PRINTS; PR00020; MAMDOMAIN.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00137; MAM; 1.
DR   SMART; SM00194; PTPc; 2.
DR   SMART; SM00404; PTPc_motif; 2.
DR   SUPFAM; SSF52799; (Phosphotyrosine protein) phosphatases II; 2.
DR   SUPFAM; SSF49899; Concanavalin A-like lectins/glucanases; 1.
DR   SUPFAM; SSF49265; Fibronectin type III; 2.
DR   SUPFAM; SSF48726; Immunoglobulin; 1.
DR   PROSITE; PS50853; FN3; 3.
DR   PROSITE; PS00740; MAM_1; 1.
DR   PROSITE; PS50060; MAM_2; 1.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 2.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 2.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Cell junction;
KW   Cell membrane; Differentiation; Disulfide bond; Glycoprotein; Hydrolase;
KW   Immunoglobulin domain; Membrane; Phosphoprotein; Protein phosphatase;
KW   Receptor; Reference proteome; Repeat; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..1446
FT                   /note="Receptor-type tyrosine-protein phosphatase U"
FT                   /id="PRO_0000371658"
FT   TOPO_DOM        19..749
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        750..770
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        771..1446
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          25..188
FT                   /note="MAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00128"
FT   DOMAIN          190..275
FT                   /note="Ig-like C2-type"
FT   DOMAIN          288..383
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          386..484
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          485..591
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          592..674
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          888..1144
FT                   /note="Tyrosine-protein phosphatase 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00160"
FT   DOMAIN          1176..1439
FT                   /note="Tyrosine-protein phosphatase 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00160"
FT   REGION          771..887
FT                   /note="Mediates interaction with CTNNB1"
FT                   /evidence="ECO:0000250"
FT   REGION          833..861
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        833..847
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        1085
FT                   /note="Phosphocysteine intermediate"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        1380
FT                   /note="Phosphocysteine intermediate"
FT                   /evidence="ECO:0000250"
FT   BINDING         1053
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000255"
FT   BINDING         1085..1091
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         1129
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         848
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         853
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         863
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:B1AUH1"
FT   MOD_RES         865
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:B1AUH1"
FT   CARBOHYD        75
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        410
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        685
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        210..264
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         774..783
FT                   /note="Missing (in isoform 2, isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:8700514, ECO:0000303|PubMed:9070223,
FT                   ECO:0000303|PubMed:9434160, ECO:0000303|Ref.9"
FT                   /id="VSP_037082"
FT   VAR_SEQ         950
FT                   /note="D -> DIRINRE (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:9434160"
FT                   /id="VSP_037083"
FT   VAR_SEQ         993..995
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037084"
FT   VAR_SEQ         1329..1330
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:9434160"
FT                   /id="VSP_037085"
FT   VARIANT         60
FT                   /note="T -> N (in dbSNP:rs35332573)"
FT                   /id="VAR_055075"
FT   VARIANT         471
FT                   /note="R -> L (in dbSNP:rs35745442)"
FT                   /id="VAR_055076"
FT   VARIANT         830
FT                   /note="H -> Y (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035650"
FT   VARIANT         835
FT                   /note="R -> W (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs558954146)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035651"
FT   VARIANT         856
FT                   /note="R -> C (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs763868325)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035652"
FT   VARIANT         940
FT                   /note="N -> S (in dbSNP:rs2235937)"
FT                   /id="VAR_055077"
FT   MUTAGEN         1085
FT                   /note="C->S: Loss of phosphatase activity toward CTNNB1.
FT                   Loss of the inhibitory effect on CTNNB1 transcriptional
FT                   activity without effect on interaction with CTNNB1; when
FT                   associated with S-1380."
FT                   /evidence="ECO:0000269|PubMed:12501215,
FT                   ECO:0000269|PubMed:16574648"
FT   MUTAGEN         1380
FT                   /note="C->S: No effect on phosphatase activity toward
FT                   CTNNB1. Loss of the inhibitory effect on CTNNB1
FT                   transcriptional activity without effect on interaction with
FT                   CTNNB1; when associated with S-1085."
FT                   /evidence="ECO:0000269|PubMed:12501215,
FT                   ECO:0000269|PubMed:16574648"
FT   CONFLICT        359..360
FT                   /note="LT -> S (in Ref. 4; AAC51938)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        401
FT                   /note="T -> A (in Ref. 4; AAC51938)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        715
FT                   /note="E -> D (in Ref. 3; AAB51343)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        840..841
FT                   /note="SG -> GW (in Ref. 4; AAC51938)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1215
FT                   /note="P -> A (in Ref. 5; AAB07074)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1245
FT                   /note="A -> R (in Ref. 4; AAC51938)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1399
FT                   /note="M -> I (in Ref. 4; AAC51938)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1436
FT                   /note="A -> V (in Ref. 5; AAB07074)"
FT                   /evidence="ECO:0000305"
FT   HELIX           876..878
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   HELIX           879..900
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          946..949
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          952..954
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          958..961
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   HELIX           966..968
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   HELIX           969..978
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          983..986
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          990..992
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          1004..1009
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          1012..1021
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          1023..1034
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          1041..1048
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          1053..1056
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   HELIX           1061..1073
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          1081..1084
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   HELIX           1091..1108
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   STRAND          1109..1111
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   HELIX           1113..1123
FT                   /evidence="ECO:0007829|PDB:6SUB"
FT   HELIX           1131..1144
FT                   /evidence="ECO:0007829|PDB:6SUB"
SQ   SEQUENCE   1446 AA;  162423 MW;  76F9BD6EFABE8663 CRC64;
     MARAQALVLA LTFQLCAPET ETPAAGCTFE EASDPAVPCE YSQAQYDDFQ WEQVRIHPGT
     RAPADLPHGS YLMVNTSQHA PGQRAHVIFQ SLSENDTHCV QFSYFLYSRD GHSPGTLGVY
     VRVNGGPLGS AVWNMTGSHG RQWHQAELAV STFWPNEYQV LFEALISPDR RGYMGLDDIL
     LLSYPCAKAP HFSRLGDVEV NAGQNASFQC MAAGRAAEAE RFLLQRQSGA LVPAAGVRHI
     SHRRFLATFP LAAVSRAEQD LYRCVSQAPR GAGVSNFAEL IVKEPPTPIA PPQLLRAGPT
     YLIIQLNTNS IIGDGPIVRK EIEYRMARGP WAEVHAVSLQ TYKLWHLDPD TEYEISVLLT
     RPGDGGTGRP GPPLISRTKC AEPMRAPKGL AFAEIQARQL TLQWEPLGYN VTRCHTYTVS
     LCYHYTLGSS HNQTIRECVK TEQGVSRYTI KNLLPYRNVH VRLVLTNPEG RKEGKEVTFQ
     TDEDVPSGIA AESLTFTPLE DMIFLKWEEP QEPNGLITQY EISYQSIESS DPAVNVPGPR
     RTISKLRNET YHVFSNLHPG TTYLFSVRAR TGKGFGQAAL TEITTNISAP SFDYADMPSP
     LGESENTITV LLRPAQGRGA PISVYQVIVE EERARRLRRE PGGQDCFPVP LTFEAALARG
     LVHYFGAELA ASSLPEAMPF TVGDNQTYRG FWNPPLEPRK AYLIYFQAAS HLKGETRLNC
     IRIARKAACK ESKRPLEVSQ RSEEMGLILG ICAGGLAVLI LLLGAIIVII RKGRDHYAYS
     YYPKPVNMTK ATVNYRQEKT HMMSAVDRSF TDQSTLQEDE RLGLSFMDTH GYSTRGDQRS
     GGVTEASSLL GGSPRRPCGR KGSPYHTGQL HPAVRVADLL QHINQMKTAE GYGFKQEYES
     FFEGWDATKK KDKVKGSRQE PMPAYDRHRV KLHPMLGDPN ADYINANYID GYHRSNHFIA
     TQGPKPEMVY DFWRMVWQEH CSSIVMITKL VEVGRVKCSR YWPEDSDTYG DIKIMLVKTE
     TLAEYVVRTF ALERRGYSAR HEVRQFHFTA WPEHGVPYHA TGLLAFIRRV KASTPPDAGP
     IVIHCSAGTG RTGCYIVLDV MLDMAECEGV VDIYNCVKTL CSRRVNMIQT EEQYIFIHDA
     ILEACLCGET TIPVSEFKAT YKEMIRIDPQ SNSSQLREEF QTLNSVTPPL DVEECSIALL
     PRNRDKNRSM DVLPPDRCLP FLISTDGDSN NYINAALTDS YTRSAAFIVT LHPLQSTTPD
     FWRLVYDYGC TSIVMLNQLN QSNSAWPCLQ YWPEPGRQQY GLMEVEFMSG TADEDLVARV
     FRVQNISRLQ EGHLLVRHFQ FLRWSAYRDT PDSKKAFLHL LAEVDKWQAE SGDGRTIVHC
     LNGGGRSGTF CACATVLEMI RCHNLVDVFF AAKTLRNYKP NMVETMDQYH FCYDVALEYL
     EGLESR
//
